ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Yiqi Huoxue Yangyin Decoction Ameliorates Diabetic Nephropathy by Targeting AMPK/mTOR-Mediated Autophagy: A Network Pharmacology-Guided in vivo and in vitro Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the protective effects and underlying mechanisms of Yiqi Huoxue Yangyin Decoction (YHY), a multi-herb formula composed of Materials and Methods: Using network pharmacology and UPLC-Q-TOF-MS, this study examined the active constituents and targets of YHY. The type 2 diabetes db/db mouse model (leptin receptor-deficient BKS.Cg-Lepr<db>/+ mice, random blood glucose ≥ 16.7 mmol/L) was used to construct a DN model in vivo. Mice received daily oral gavage of YHY or vehicle for 4 weeks (n=10). YHY's protective benefits were assessed by physiological measurements, serum insulin and HbA1c by ELISA, histopathological evaluation of glomerular and tubular regions, glomerular basement membrane thickness by TEM, and protein expression in renal cortex by immunohistochemistry, immunofluorescence, and Western blot. In vitro, using a high-glucose-induced MPC-5 model, CCK-8, wound healing assays, qRT-PCR, and Western blot were performed (n=3-6) to investigate the mechanisms of YHY. Results: YHY demonstrated significant protective effects against DN. The expression levels of autophagy markers (ULK1, P62, and LC3B) in renal tissue were restored following YHY intervention. Through the AMPK/mTOR pathway, YHY regulated the expression of autophagy-related genes (ULK1, Beclin-1, P62, LC3B, ATG5, ATG7) and senescence-related genes (P21, P53), and improved the survival and migratory capabilities of high-glucose-induced MPC-5 cells. Furthermore, YHY enhanced the expression of podocyte structural proteins, including Nephrin, NPHS2, and SYNPO. Conclusion: YHY treatment was associated with activation of autophagy and attenuation of podocyte senescence, potentially through modulation of the AMPK/mTOR signaling pathway, a finding that requires validation in future mechanistic studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.